Placebo to AIN457 150mg/1mL Solution for injection in pre-filled syringe clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff problems. It compares the medicine to a dummy treatment (placebo) to see if it helps reduce pain and improve shoulder movement over 24 weeks.
For: Moderate to severe rotator cuff tendinopathyPortugal · Denmark · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff tendinopathy. Researchers want to see if it helps reduce pain and improve shoulder movement compared to a dummy medicine.
For: Moderate to severe rotator cuff tendinopathySpain · Hungary · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
For: Giant cell arteritis (GCA)Estonia · Sweden · Hungary